Lucid Diligence Brief - LucidQuest Lucid Diligence Brief delivers seven investor questions on recent news, a 60-second thesis frame, red flags, and the next catalyst in one page.

Faster diligence ⚡ LDB = one page on assets and companies: what changed, 7 Qs, red flags, next catalyst.

Explore: http://dlvr.it/TS94sH

Comment LDB for more information.
(Pros only. Not investment research or advice. UK: Art19(5)/49(2)(a–d).)

$300B+ in drug revenue is nearing Loss of Exclusivity.

PatentCliffClock tracks major pharma patent expirations in real time.
LucidWargames helps teams rehearse their LOE response before it hits.

Explore: http://dlvr.it/TS91Q6

Simulate: http://dlvr.it/TS91Q8

Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing Professional audiences only. Not investment research or advice. UK readers: […] The post Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing Comment below! #LucidQuest #PharmaCI

BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025? Get instant access to a concise analysis of 22 BioPharma (+ Google) CVCs and their portfolios. In minutes, you’ll see where strategic capital is flowing across Technology and Therapy Areas—and how 2025 trends compare to 2023. What’s inside: Clear mapping of CVC focus by Technology and Therapy Areas Trend shifts vs. 2023 to validate your thesis Actionable insights to spot momentum early How it works: Fill out the form to receive your report immediately. Questions or feedback? info@lqventures.com LucidQuest empowers BioPharma executives and Life Sciences investors with up-to-date analysis. Stay tuned for 2025 deep dives on Cell & Gene Therapy, Digital Health, Oncology & Hematology, and more.

What’s shaping CVC investments for 2025? Key trends: AI/ML, Gene Therapy, and a focus on Immune Disorders & Neurodegenerative Diseases. Curious for more? 📥 Download the full report for insights! http://dlvr.it/TS84zp
#CVC #InvestingInInnovation #VentureCapital #GeneTherapy #AI

BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025? Get instant access to a concise analysis of 22 BioPharma (+ Google) CVCs and their portfolios. In minutes, you’ll see where strategic capital is flowing across Technology and Therapy Areas—and how 2025 trends compare to 2023. What’s inside: Clear mapping of CVC focus by Technology and Therapy Areas Trend shifts vs. 2023 to validate your thesis Actionable insights to spot momentum early How it works: Fill out the form to receive your report immediately. Questions or feedback? info@lqventures.com LucidQuest empowers BioPharma executives and Life Sciences investors with up-to-date analysis. Stay tuned for 2025 deep dives on Cell & Gene Therapy, Digital Health, Oncology & Hematology, and more.

Validate your investment thesis—fast. ✅ LucidQuest’s FREE read on 22 BioPharma (+ Google) CVCs: focus areas + 2023→2025 shifts, clear takeaways. ⏱️ Get it now:

Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash Professional audiences only. Not investment research […] The post Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash Comment below! #LucidQuest #PharmaCI

BioPharma (+ Google) Corporate Venture Capital Investment Trends: Who is leading in 2025? Get instant access to a concise analysis of 22 BioPharma (+ Google) CVCs and their portfolios. In minutes, you’ll see where strategic capital is flowing across Technology and Therapy Areas—and how 2025 trends compare to 2023. What’s inside: Clear mapping of CVC focus by Technology and Therapy Areas Trend shifts vs. 2023 to validate your thesis Actionable insights to spot momentum early How it works: Fill out the form to receive your report immediately. Questions or feedback? info@lqventures.com LucidQuest empowers BioPharma executives and Life Sciences investors with up-to-date analysis. Stay tuned for 2025 deep dives on Cell & Gene Therapy, Digital Health, Oncology & Hematology, and more.

🚨 Who’s leading BioPharma (+ Google) CVC in 2025?

🔎 #LucidQuest analyzed 22 CVCs—focus by Tech & Therapy Areas + shifts vs. 2023.

Grab the FREE snapshot ⚡

Your launch may look great on Google, but AI answers can cite others. #LucidScope tracks perception + answer differences across models and personas, with source tracing and risk flags. Start with an AI Answer Audit: http://dlvr.it/TS7QLb #LucidQuest

Trending in Hematology: Jaypirca Phase 3, OPN-6602 and more This hematology edition covers positive Phase 3 results for Jaypirca in previously treated CLL or SLL, FDA Fast Track designation for OPN-6602 in multiple myeloma, and expanded funded CLL options in New Zealand. Additional updates include local CAR-T development in Brazil, new pediatric VTE prophylaxis guidelines from ASH and ISTH, retrospective Hemlibra data in pediatric hemophilia A with inhibitors, interim MRD findings in large B-cell lymphoma, and positive Phase II results in higher-risk myelodysplastic syndrome.

LucidQuest YouTube > Trending in Hematology: Jaypirca Phase 3, OPN-6602 and more: This hematology edition covers positive Phase 3 results for Jaypirca in previously treated CLL or SLL, FDA Fast Track designation for OPN-6602 in multiple myeloma, and… Subscribe for more! #LucidQuest #PharmaCI

Oncology Today—April 20, 2026 This week’s Oncology update highlights regulatory progress, pivotal clinical data, financing support, and partnership activity across multiple solid tumor programs. […] The post Oncology Today—April 20, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Oncology Today—April 20, 2026 Comment below! #LucidQuest #PharmaCI

Hematology Today—April 20, 2026 This week’s Hematology update highlights regulatory progress, early- and late-stage clinical data, expanding cell therapy pipelines, and strategic partnerships across […] The post Hematology Today—April 20, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Today—April 20, 2026 Comment below! #LucidQuest #PharmaCI

AI in Healthcare and Digital Health Today—April 20, 2026 This week’s Artificial Intelligence and Digital Health update highlights regulatory progress, clinical validation advances, expanding partnerships, and continued investment in AI-driven […] The post AI in Healthcare and Digital Health Today—April 20, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> AI in Healthcare and Digital Health Today—April 20, 2026 Comment below! #LucidQuest #PharmaCI

Lucid Diligence Brief: 10x Genomics launches Atera Platform Lucid Diligence Brief: 10x Genomics launches Atera Platform Professional audiences only. Not investment research or advice. UK readers: for persons […] The post Lucid Diligence Brief: 10x Genomics launches Atera Platform appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: 10x Genomics launches Atera Platform Comment below! #LucidQuest #PharmaCI

Zero-click is here: AI summaries decide what gets seen. #LucidScope benchmarks how major models describe you vs competitors, spots outdated or hallucinated claims, and recommends content + schema actions. Request an audit: http://dlvr.it/TS75d3 #LucidQuest

Women’s Health Today—April 15, 2026 This biweekly Women’s Health video recap highlights regulatory advances, clinical momentum, screening access efforts, biomarker insights, and evolving patient experience […] The post Women’s Health Today—April 15, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Women’s Health Today—April 15, 2026 Comment below! #LucidQuest #PharmaCI

AI is already answering Qs about your brand. Competitors showing up instead of you? LucidScope maps answers across models, traces sources, flags drift, and suggests zero-click fixes. Want an AI Answer Audit?

LucidQuest

Accelerate success in #Pharma & #Biotech!

🔬 Join LucidQuest on YouTube for #insights across therapeutic areas, as well as #ArtificialIntelligence, #MachineLearning, #DigitalHealth & more.

Subscribe & shape the future of #healthcare: http://dlvr.it/TS6gR8 🚀



#Strategy

🚀 #ATS2025 buzz check! #COPD, #Asthma & #Pulmonology dominate, with #Data (~21%) & #Efficacy (~18%) driving talk. 82% positive vibes on AI & therapy breakthroughs. 📊🫁 Dive into our full report! http://dlvr.it/TS6Z15 #SocialListening #LucidQuest #ATS25 @atscommunity @ATS_AII

🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TS6NpG #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT

Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J Professional audiences only. Not investment research or advice. UK readers: for […] The post Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J Comment below! #LucidQuest #PharmaCI

What is Competitive Intelligence? A Guide by LucidQuest - LucidQuest Ventures The integration of AI in Medical Affairs teams revolutionizes healthcare from harnessing real-world evidence to transforming HCPs engagement.

Ever wonder how some companies always know what’s coming next? It’s not luck, it’s Competitive Intelligence.

Check out our guide 👉 http://dlvr.it/TS6Lgg to learn about the process, tools, benefits, and how every team can use CI to win.

What if strategy felt like live chess?
#LucidWargames runs dynamic sims, pits you vs adaptive AI rivals, adjudicates by KPIs, and maps odds with 100+ Monte Carlo runs.
Prep or power your next session with rigor: http://dlvr.it/TS63Wv
Demo: http://dlvr.it/TS63Wz
#LucidQuest

From slides to simulations. #LucidWargames, a multi-agent engine, pressure tests strategy with evolving scenarios, objective scoring, and probability maps from 100+ Monte Carlo runs. Optimize your next workshop: http://dlvr.it/TS5xrb Demo: http://dlvr.it/TS5xrc #LucidQuest

🚀 Dive into #ASCOGU25 buzz!

Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.

#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺

Download our full report http://dlvr.it/TS5ld7 !

#Oncology #SocialListening #LucidQuest

Stay ahead in healthcare innovation.
Subscribe to #LucidQuest's Weekly LQ AI Report for #AI breakthroughs, #PrecisionMedicine insights & #DigitalHealth trends.
Get tips & success stories delivered to your inbox. http://dlvr.it/TS5jV4

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma Professional audiences only. Not investment research […] The post Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma Comment below! #LucidQuest #PharmaCI

BioPharma CVC snapshot: GV 60+; AbbVie leads exits. Bets: Small Molecules, Gene Therapy, Digital/AI. Oncology dominates; immune disorders rising since 2023. Shared bets surge; GV/Lilly/Sanofi most diversified. Get the full report—

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TS58pq
@ASCO

#SocialListening #LucidQuest

Trending in Vaccines: Marburg Trial, Nuvaxovid Canada and more This edition highlights key developments in vaccines research, including the initiation of a first-in-human Phase 1 trial for a Marburg virus vaccine and Sanofi’s transition to market authorization holder for Nuvaxovid in Canada. Additional updates span pediatric vaccine safety data, oncology vaccine progress, infrastructure expansion, and advancements in influenza and maternal immunization. Together, these updates reflect ongoing momentum in early-stage innovation, clinical development, and strategic positioning across global vaccine programs.

LucidQuest YouTube > Trending in Vaccines: Marburg Trial, Nuvaxovid Canada and more: This edition highlights key developments in vaccines research, including the initiation of a first-in-human Phase 1 trial for a Marburg virus vaccine and Sanofi’s… Subscribe for more! #LucidQuest #PharmaCI

Respiratory Today—April 17, 2026 This week’s Respiratory Research update highlights regulatory momentum, clinical trial progress, pipeline expansion, and increased competition in inhaled therapies. In […] The post Respiratory Today—April 17, 2026 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Respiratory Today—April 17, 2026 Comment below! #LucidQuest #PharmaCI